On March 30, 2023,
Maxim Group
upgraded
their outlook for Palisade Bio (NASDAQ:PALI) from Hold to Buy.
Analyst Price Forecast Suggests 1,417.86% Upside
As of March 30, 2023,
the average one-year price target for Palisade Bio is $25.50.
The forecasts range from a low of $25.25 to a high of $26.25.
The average price target represents an increase of 1,417.86% from its latest reported closing price of $1.68.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Palisade Bio
is $0MM, a decrease of 100.00%.
The projected annual non-GAAP EPS
is -$7.14.
What are Large Shareholders Doing?
VEXMX – Vanguard Extended Market Index Fund Investor Shares
holds 78K shares
representing 1.72% ownership of the company.
In it’s prior filing, the firm reported owning 69K shares, representing
an increase
of 10.50%.
The firm
decreased
its portfolio allocation in PALI by 72.43% over the last quarter.
FNCMX – Fidelity Nasdaq Composite Index Fund
holds 65K shares
representing 1.45% ownership of the company.
No change in the last quarter.
FSMAX – Fidelity Extended Market Index Fund
holds 61K shares
representing 1.35% ownership of the company.
In it’s prior filing, the firm reported owning 61K shares, representing
a decrease
of 0.84%.
The firm
decreased
its portfolio allocation in PALI by 67.86% over the last quarter.
ITOT – iShares Core S&P Total U.S. Stock Market ETF
holds 0K shares
representing 0.00% ownership of the company.
No change in the last quarter.
What is the Fund Sentiment?
There are 6 funds or institutions reporting positions in Palisade Bio.
This is a decrease
of
34
owner(s) or 85.00% in the last quarter.
Average portfolio weight of all funds dedicated to PALI is 0.00%,
a decrease
of 99.87%.
Total shares owned by institutions decreased
in the last three months by 100.00% to 0K shares.
Palisade Bio Background Information
(This description is provided by the company.)
Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
